Search Results
Your search for it matches 15746 pages
Showing 551 - 600Genitourinary Cancer Expert Yüksel Ürün, MD, Shares His Career Journey and the Importance of Achieving a Work/Life Balance
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD, about his clinical and research career in oncology. Dr. Ürün is Professor of Medicine at the Ankara University School of Medicine in Turkey. After...
Overall Survival Not Improved With Maintenance Niraparib in Advanced Ovarian Cancer
The final overall survival analysis of the phase III PRIMA trial found no survival benefit for maintenance niraparib over placebo in advanced ovarian cancer. However, the PARP inhibitor continued to exert a sustained progression-free survival benefit, investigators reported at the European Society...
At-Home Testing Kits, Coordinated Outreach May Improve Colorectal Cancer Screening Rates
Researchers have demonstrated that a targeted intervention may increase screening rates in patients who do not adhere to current colorectal cancer screening recommendations, according to a recent study published by Reuland et al in JAMA Network Open. Background Colorectal cancer screening is often...
Adding Temozolomide to Radiation Therapy May Improve Survival in Adults With Low-Grade Gliomas
Both radiation and temozolomide may have meaningful single-modality antitumor activity against slow-growing, low-grade gliomas, according to recent findings presented by Schiff et al at the 2024 Society for Neuro-Oncology Annual Meeting (Abstract LTBK-07) and simultaneously published in...
KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer
In the final per-protocol analysis of the phase III KEYNOTE-811 trial, an overall survival benefit was shown by adding the PD-1 inhibitor pembrolizumab to trastuzumab and chemotherapy in treatment-naive, unresectable, HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.1...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, confirms the benefit for the STRIDE regimen of the monoclonal antibodies durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 [The STRIDE regimen consists of a single priming dose of...
LEAP-012: Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma
The combination of the VEGF tyrosine kinase inhibitor lenvatinib, the PD-1 inhibitor pembrolizumab, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma (HCC) compared with TACE alone, according to...
T-DXd of Benefit in Patients With Breast Cancer and Brain Metastases
Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive metastatic breast cancer and brain metastases who have experienced disease progression on at least...
Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, was bolstered by the positive overall survival analysis...
HypoG-01 Trial: Reducing the Treatment Time for Breast Cancer Nodal Irradiation
A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1 The 5-year results of...
I-SPY2.2: Dato-DXd Plus Durvalumab Yields High Pathologic Response Rate in Breast Cancer Subset
In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and ‘all-negative’ subtypes.1...
Cancer Has Plagued My Family
My twin brother and I were adopted at 18 months old, so I don’t know the medical history of our biological parents and family. But for certain, cancer has played an integral—and heartbreaking—role in my life. Both of my adoptive parents were diagnosed with genitourinary cancers at relatively early ...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
In earlier issues of The ASCO Post, we shared unique insights from recipients of the International Development and Education Award (IDEA), whose experiences at the 2024 ASCO Annual Meeting (ASCO24) had a profound impact on their professional and personal growth. Here are more reflections from...
Impact of Food Insecurity on the Incidence of Hepatocellular Carcinoma
At the 2024 American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Rebecca D. Kehm, PhD, of Columbia University Mailman School of Public Health, New York, and colleagues presented some of the ...
How Functional and Genomic Precision Medicine Are Getting Closer to Matching Each Patient to the Right Therapy
Functional precision medicine—in which information is obtained from direct perturbations of tumor-derived living cells that enable immediate translatable, personalized data to guide patient therapy—has its roots dating back more than 50 years.1 However, advances in two- and three-dimensional...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III -CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Information-Blocking Proposal Helps Protect Reproductive Health Information, Patient Preferences
The Association for Clinical Oncology (ASCO) submitted comments to the Office of the National Coordinator for Health Information Technology in response to the Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability (HTI-2) proposed...
Katherine Van Loon Named Editor-in-Chief of JCO Global Oncology
Katherine Van Loon, MD, MPH, has been appointed as the next Editor-in-Chief of JCO Global Oncology (JCO GO). JCO GO is an online-only, open-access ASCO journal focusing on cancer research, care, and delivery in low-resource countries and settings. The journal aims to address the challenges faced...
Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor
The Global Coalition for Adaptive Research (GCAR) announced an agreement to evaluate AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor developed by AstraZeneca, in GCAR’s Glioblastoma Adaptive Global Innovative Learning Environment trial (GBM AGILE; ClinicalTrials.gov identifier...
Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer
Researchers have found that in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer, according to a recent study published by Lin et al in Nature. The findings challenged conventional thinking on the...
Novel p53-MDM2 Inhibitor Plus Ribociclib Demonstrates Anticancer Activity in Liposarcoma Subset
The p53-MDM2 inhibitor siremadlin given with the CDK4/6 inhibitor ribociclib showed activity in a subset of patients with well-differentiated/dedifferentiated liposarcomas enrolled in the biology-driven adaptive phase II MEGAMOST Ribociclib/HDM201 basket trial.1 MEGAMOST was designed to evaluate...
Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC
Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for ...
Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis, Monitoring, and Treatment
An international, multidisciplinary team of neuro-oncology researchers and physicians has developed new clinical practice recommendations for the use of artificial intelligence (AI) methods to more accurately diagnose, monitor, and treat patients with brain cancer. The guidelines were described in...
Firefighters May Be Exposed to Chemicals Associated With Breast Cancer
Investigators have found that firefighters may face occupational exposures to multiple chemicals that could increase their risk of developing breast cancer, according to a recent study published by Cardona et al in Toxics. Background Prior research has revealed that firefighters have significantly...
Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer
Vered Stearns, MD, is the Director for Translational Breast Cancer Research in the Department of Hematology and Medical Oncology at Sandra and Edward Meyer Cancer Center and Weill Cornell Medical School. Dr. Stearns talks about updates in the management of patients with triple-negative breast...
Project Facilitate: 5 Years of Progress, Outreach, and Service
OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Lieutenant Commander Mitchell Chan, PharmD, BCPS, Team Lead and Clinical Analyst, Lieutenant Cameron Wilson, PharmD, BCPS, BCCCP, ...
Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?
Question: Based on NATALEE and monarchE data, is there still a need for neoadjuvant chemotherapy in hormone receptor (HR)-positive, HER2-negative early breast cancer? Answer: In monarchE trial, the CDK4/6 inhibitor abemaciclib combined with endocrine therapy demonstrated long-term efficacy in...
Determining the Optimal First-Line Management of Advanced Classical Hodgkin Lymphoma
“While clinical trials emphasize improvement in cure rates for patients with advanced classical Hodgkin lymphoma, an important goal is reducing the potential long-term effects of treatment,” commented Iris Isufi, MD, of the Smilow Cancer Hospital and Yale Cancer Center, New Haven, Connecticut, and ...
New Technique May Allow for Visualization of CAR T Cells Postinjection
The University of Cincinnati Cancer Center announced the launch of a new study funded by a $2.3 million National Cancer Institute (NCI) grant to develop a novel technique to visualize where genetically modified immune cells go after being administered in patients with cancer. Background During...
AI Tool May Detect Cancer Gene Signatures in Biopsy Images
Researchers have developed an artificial intelligence (AI)-powered computational program that may be capable of predicting the activity of thousands of genes within tumor cells based on standard microscopy images of a biopsy, according to a recent study published by Pizurica et al in Nature...
Study Identifies New Approach to Overcome Docetaxel Resistance in Patients With Advanced Prostate Cancer
The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other targets to treat prostate cancer are still necessary to prolong life and slow the progression of...
Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care
Recent advances in urothelial carcinoma treatments may offer a path to curative care for more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published by Milowsky in The New England Journal of Medicine. The findings indicated that...
In Case You Missed It: Roundup From ESMO Congress 2024
In addition to our in-depth analysis of important clinical trials presented at the European Society for Medical Oncology (ESMO) Congress 2024, there is always room for more coverage from The ASCO Post, including these brief summaries of other presentations of interest. They focus on a potential...
Exploring Issues in Oncofertility
“Cancer in young adults is more complicated in part [because of the risk of] infertility and premature menopause,” commented Ann H. Partridge, MD, MPH, FASCO, Interim Chair, Department of Medical Oncology; the Eric P. Winer, MD Chair in Breast Cancer Research, Dana-Farber Cancer Institute; and ...
Breast Cancer Vaccine Could Be Preventive, Well Tolerated in High-Risk Patients
Researchers have uncovered insights into a novel investigational vaccine aimed at preventing triple-negative breast cancer. The findings by Rhoades et al were presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting (Abstract 631) and simultaneously published in the Journal...
New Insights Into Innate Resistance for Immunotherapies in Colorectal Cancer
Researchers have assessed the efficacy of targeting the CD47 protein combined with traditional immunotherapy drugs in patients with colorectal cancer, with a recent study published by Arai et al in the Journal for ImmunoTherapy of Cancer. The findings indicated that the combination approach could...
Ifinatamab Deruxtecan Shows Activity in Extensive-Stage Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (SCLC) in an interim analysis of the phase II IDeate-Lung01 study.1 The findings were presented at the International Association for...
TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC
The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC
Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for ...
Osimertinib Plus Savolitinib: Responses Reported in First-Line Treatment of MET-Aberrant, EGFR-Mutant NSCLC
The combination of the EGFR tyrosine kinase inhibitor osimertinib and the MET inhibitor savolitinib has demonstrated clinically meaningful improvements compared with osimertinib alone as a first-line treatment of patients with de novo MET-aberrant, EGFR-mutant advanced non–small cell lung cancer...
Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC
The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC
In a phase III study conducted in China, the bispecific antibody (targeting both PD-1 and the vascular endothelial growth factor [VEGF]) ivonescimab was compared with the PD-1 inhibitor pembrolizumab as first-line treatment of PD-L1–positive advanced non–small cell lung cancer (NSCLC). Ivonescimab ...
Patient-Level Data Support Perioperative Use of Nivolumab in Resectable NSCLC
An examination of patient-level data from the phase III CheckMate 816 and CheckMate 77T trials supports the perioperative use of the PD-1 inhibitor nivolumab plus chemotherapy, as compared with the neoadjuvant use of nivolumab plus chemotherapy without adjuvant therapy, in resectable non–small...
Participation in Virtual Prehabilitation and Outcomes Following Thoracic Cancer Surgery
Guest Editor’s Note: Oncology guidelines recommend prehabilitation exercises to minimize postoperative complications. However, the COVID-19 pandemic imposed severe restrictions on patient access to in-person exercise programs offered by hospitals and clinics. In this article, Dr. Krupali Desai...
NCCN Guidelines Have Expanded to Meet Growing Understanding of Hereditary Risk
The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers. The new guidelines followed the recent...
Tanning Bed Access, Usage May Be Driving Higher Rates of Melanoma in New England
Investigators have uncovered a potential link between the availability and use of tanning beds and the rising rates of melanoma in New England, according to a recent study published by Wei et al in the Journal of Investigative Dermatology. The findings may provide critical insights to inform public ...
Study Explores Underpinnings of Immunotherapy-Releated Myocarditis in Patients With Cancer
Researchers may have uncovered the immune basis for the development of myocarditis in patients with cancer receiving immune checkpoint inhibitors, according to a recent study published by Blum et al in Nature. The findings revealed changes in specific types of immune and stromal cells in the heart...
